Delcath Systems Inc (DCTH)

0.02
0.00 2.49
NASDAQ : Health Care
Prev Close 0.02
Open 0.03
Day Low/High 0.02 / 0.03
52 Wk Low/High 3.35 / 10.88
Volume 48.31M
Avg Volume 14.69M
Exchange NASDAQ
Shares Outstanding 167.88M
Market Cap 3.36M
EPS -10.60
Div & Yield N.A. (N.A)

Latest News

Delcath Announces 2016 Financial Results

Delcath Announces Special Protocol Assessment Agreement With FDA For Pivotal Trial With Melphalan/HDS In Intrahepatic Cholangiocarcinoma

Company Plans to file 2016 Fourth Quarter and Year End Financial Results by March 30, 2017

Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies

Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months

Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential Of Delcath Investigational PHP Therapy

Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders

Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort

Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort

Company Accepts Invitation from Cholangiocarcinoma Foundation to Present Initial Signals in ICC

Delcath Issues Letter To Stockholders

Delcath Issues Letter To Stockholders

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution...

European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Unprecedented Progression Free and Overall Survival Observed in University Hospital Southampton Retrospective Analysis

Delcath European Patient Education Website Receives Prestigious Digital Health Award

Delcath European Patient Education Website Receives Prestigious Digital Health Award

Againsttheodds.eu Recognized for High Quality Consumer Health Content